Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Yale University | OTHER |
| Shanghai Jiao Tong University School of Medicine | OTHER |
Not provided
Not provided
Not provided
Not provided
A single-center, single-blind, randomized study to investigate the effectiveness of a hemodynamic-guided treatment strategy to improve blood pressure control
Hypertension is a hemodynamic-related disorder characterized by abnormalities of the cardiac output (CO) and/or systemic vascular resistance (SVR). It is hypothesized that selecting antihypertensive therapy based on patients' hemodynamic profile could lead to more effective blood pressure (BP) control than standard care in a real-world population of hypertensive patients in outpatient setting. A single-center, randomized trial was conducted to include adults with uncontrolled hypertension who seek outpatient care at Peking University People's Hospital between December 2018 and December 2019 in Beijing, China.
Participants were randomly assigned to the standard care group or the hemodynamic group in a 1:1 ratio. Impedance cardiography (ICG) was performed with all participants to measure hemodynamic parameters. Only physicians in the hemodynamic group were provided with patients' ICG findings and a computerized clinical decision support of recommended treatment choices based on patients' hemodynamic profiles. The primary outcomes were the reductions in systolic BP (SBP) and diastolic BP (DBP) levels at the follow-up visit 8(±4) weeks after baseline. Secondary outcomes included achievement of BP goal of <140/ 90 mmHg and the reductions in BP by baseline BP, age, sex, and BMI.
The ICG device used (HDproTM CHM T3002/P3005, designed by Beijing Li-Heng Medical Technologies, Ltd, manufactured by Shandong Baolihao Medical Appliances, Ltd.) was developed based on improved hardware and advanced digital filtering algorithms, and has been validated versus both invasive thermodilution and non-invasive echocardiography in different settings.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ICG-guided | Experimental | anti-hypertensive drug selection based on physician's experience and hemodynamic profiling by measured ICG |
|
| Empirical | Active Comparator | anti-hypertensive drug selection based on physician's experience only |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ICG-guided drug selection | Other | anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline systolic blood pressure at 8 weeks | Change from baseline systolic blood pressure at 8 weeks in the window of 4-12 weeks | 8 weeks post-baseline |
| Change from baseline diastolic blood pressure at 8 weeks | Change from baseline diastolic blood pressure at 8 weeks in the window of 4-12 | 8 weeks post-baseline |
| Measure | Description | Time Frame |
|---|---|---|
| BP control rate at 8 weeks | proportion of subjects with BP < 140/90 mmHg at 8 weeks post-baseline visit | 8 weeks post-baseline |
| Change from baseline heart rate (HR) at 8 weeks | Change from baseline heart rate (heart beats per minute) at 8 weeks in the window of 4-12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ningling Sun | Department of Hypertension at Heart Centr, Peking University People's Hospital, Beijing, China | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University People's Hospital | Beijing | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34580169 | Derived | Lu Y, Wang L, Wang H, Gu J, Ma ZJ, Lian Z, Zhang Z, Krumholz H, Sun N. Effectiveness of an impedance cardiography guided treatment strategy to improve blood pressure control in a real-world setting: results from a pragmatic clinical trial. Open Heart. 2021 Sep;8(2):e001719. doi: 10.1136/openhrt-2021-001719. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| empirical drug selection | Other | anti-hypertensive drug selection based on physician's experience only |
|
| 8 weeks post-baseline |
| Change from baseline cardiac index (CI) at 8 weeks | Change from baseline cardiac index (cardiac output devided by body surface area) at 8 weeks in the window of 4-12 weeks | 8 weeks post-baseline |
| Change from baseline arterial stiffness (AS) at 8 weeks | Change from baseline arterial stiffness at 8 weeks in the window of 4-12 weeks | 8 weeks post-baseline |
| Change from baseline systemic vascular resistance index (SVRI) at 8 weeks | Change from baseline systemic vascular resistance index at 8 weeks in the window of 4-12 weeks | 8 weeks post-baseline |
| Change from baseline thoracic blood volume standing/supine ratio (TBR) at 8 weeks | Change from baseline thoracic blood volume standing vs supine ratio at 8 weeks in the window of 4-12 weeks | 8 weeks post-baseline |